Silenseed to Present at Biotech Showcase 2015 in San Francisco Jerusalem, Israel, – Jan 8, 2015 - Silenseed LTD, a clinical stage biopharmaceutical company developing RNAi-based therapies for solid tumors, including pancreatic, prostate and brain tumors, will present at Biotech Showcase 2015 on Wednesday January 14, 2015 at 4:45pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco – Union Square. Chief Executive Officer of Silenseed, Amotz Shemi, PhD, will provide a corporate overview including recent advancements of the Company’s successful Phase 1/2a clinical trial evaluating siG12D-LODER™ in patients with locally advanced pancreatic cancer, and the preparation toward Phase 2b. About siG12D-LODER for patients with pancreatic cancer An efficient non-toxic treatment for pancreatic cancer is an urgent unmet need. Silenseed develops the LODER (Local Drug EluteR) platform, specifically the siG12D-LODER™, a miniature biodegradable polymeric matrix encompassing a novel anti-KRAS siRNA drug. So far the well known dominating cancer driver KRAS was considered as an undrugable target. LODER is placed within the tumor by endoscope ultrasound, enabling prolonged drug release within the tumor along months, while protecting the vulnerable siRNA from degradation and ensuring complete drug coverage of the tumor. siG12D-LODER™ passed a successful Phase 1/2a study, presented an effective therapeutic modality for pancreatic cancer in combination with Gemcitabine or FOLFIRINOX. Safety profile confirmed; encouraging efficacy evidences included tumor response, and extension of progression free survival and overall survival. LODER solves major challenges of oligonucleotide therapeutics for a large subset of diseases including solid tumors. About Silenseed Silenseed is a clinical stage (Phase2b) biopharmaceutical company developing RNAi-based therapies for solid tumors. The company completed a successful Phase 1/2a study in pancreatic cancer, showing tumor halting and life extension. Therapies are based on proprietary drugs and LODER™ delivery platform; pipeline includes pancreatic, prostate and brain tumors. Further information is available at www.silesneed.com Forward-Looking Statements This presentation contains forward-looking statements relating to expected future performance. Such statements are based on current views and assumptions that are subject to uncertainties which are difficult to predict, including expected operating and clinical results, successful implementation of our growth opportunities, industry conditions, availability of financing alternatives, debt service and future capital needs. Please refer to Silenseed’s continuous disclosure documents as these identify factors which may cause actual results to differ materially from any forward-looking statements. For Further Information contact [email protected] Direct: +972-546-793-703 For Investors Information contact Doug Bantum Capital Markets, WallachBeth Capital LLC, 100 Wall Street Suite 6600, New York, NY 10005 Office: 646-998-7605 Cell: 917-929-2837 Email: [email protected]